Home > Insider Trading > Filing (0001209191-14-024143)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1273636	Applied Genetic Technologies Corp	AGTC	Biological Products, (No Disgnostic Substances) (2836)	593553710

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1598526	Samuel Wu	C/O Applied Genetic Technologies Corp. 11801 Research Drive, Suite D Alachua FL 32615		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2014-04-01	1,376,461	$0.00	1,376,461	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2014-04-01	75,735	$12.00	1,452,196	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1A Convertible Preferred Stock	Disposition	2014-04-01	11,478,652	$0.00	690,678	$0.00
Common Stock	Series B-1 Convertible Preferred Stock	Disposition	2014-04-01	6,409,436	$0.00	183,126	$0.00
Common Stock	Series B-2 Convertible Preferred Stock	Disposition	2014-04-01	11,893,926	$0.00	339,826	$0.00
Common Stock	Series B-3 Convertible Preferred Stock	Disposition	2014-04-01	5,699,111	$0.00	162,831	$0.00
Series B-1 Convertible Preferred Stock	Series B-1 Warrant	Disposition	2014-04-01	416,361	$0.00	416,361	$0.13
Common Stock	Common Stock Warrant	Acquisiton	2014-04-01	11,896	$0.00	11,896	$4.54

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0	2017-05-02	No	4	C	Indirect
11,896	2017-05-02	No	4	C	Indirect

Footnotes

Each share of convertible preferred stock converted automatically into common stock upon the closing of the Issuer's initial public offering, and had no expiration date.
Shares are held of record by MedImmune Ventures, Inc. The reporting person is a managing director of MedImmune Ventures, Inc. The reporting person disclaims beneficial ownership of all the shares held by MedImmune Ventures, Inc. and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his proportionate pecuniary interest therein.
Shares purchased in the Issuer's initial public offering at the initial public offering price of $12.00 per share.
Not applicable.
Each share of Series B-1 convertible preferred stock automatically converted into shares of common stock upon the closing of the Issuer's initial public offering on a 1-for-35 basis.
Warrant was fully exercisable upon original issue.